[HTML][HTML] The “old” and the “new” antibiotics for MDR gram-negative pathogens: for whom, when, and how
The recent expansion of multidrug resistant and pan-drug-resistant pathogens poses
significant challenges in the treatment of healthcare associated infections. An important …
significant challenges in the treatment of healthcare associated infections. An important …
[HTML][HTML] Clinical data from studies involving novel antibiotics to treat multidrug-resistant Gram-negative bacterial infections
Abstract Multidrug-resistant (MDR) Gram-negative bacteria (GNB) pose a critical threat to
global healthcare, worsening outcomes and increasing mortality among infected patients …
global healthcare, worsening outcomes and increasing mortality among infected patients …
Recent advances in the pharmacological management of infections due to multidrug-resistant Gram-negative bacteria
DR Giacobbe, M Mikulska, C Viscoli - Expert review of clinical …, 2018 - Taylor & Francis
Introduction: The emergence and diffusion of multidrug-resistant Gram-negative bacteria
(MDR-GNB) is an unprecedented threat, with prevalences as high as 10–50% being …
(MDR-GNB) is an unprecedented threat, with prevalences as high as 10–50% being …
New drugs for multidrug-resistant gram-negative organisms: time for stewardship
A gradual rise in drug-resistant trends among Gram-negative organisms, especially
carbapenem-resistant (CR) Enterobacteriaceae (CRE), CR-Pseudomonas aeruginosa, and …
carbapenem-resistant (CR) Enterobacteriaceae (CRE), CR-Pseudomonas aeruginosa, and …
Emerging treatment options for multi-drug-resistant bacterial infections
R Giurazza, MC Mazza, R Andini, P Sansone, MC Pace… - Life, 2021 - mdpi.com
Antimicrobial resistance (AMR) remains one of the top public health issues of global
concern. Among the most important strategies for AMR control there is the correct and …
concern. Among the most important strategies for AMR control there is the correct and …
[HTML][HTML] Global threat of carbapenem-resistant Gram-negative bacteria
Infections caused by multidrug-resistant (MDR) and extensively drug-resistant (XDR) Gram-
negative bacteria (GNB), including carbapenem-resistant (CR) Enterobacterales (CRE; …
negative bacteria (GNB), including carbapenem-resistant (CR) Enterobacterales (CRE; …
Plazomicin: a novel aminoglycoside for the treatment of resistant Gram-negative bacterial infections
Plazomicin is a novel semisynthetic parenteral aminoglycoside that inhibits bacterial protein
synthesis. It was approved by the United States Food and Drug Administration for use in …
synthesis. It was approved by the United States Food and Drug Administration for use in …
Plazomicin: a new aminoglycoside in the fight against antimicrobial resistance
JA Clark, DS Burgess - Therapeutic advances in infectious …, 2020 - journals.sagepub.com
Objective: To review the mechanism of action, mechanisms of resistance, in vitro activity,
pharmacokinetics, pharmacodynamics, and clinical data for a novel aminoglycoside. Data …
pharmacokinetics, pharmacodynamics, and clinical data for a novel aminoglycoside. Data …
Antimicrobial treatment challenges in the era of carbapenem resistance
Infections due to carbapenem-resistant Gram-negative bacteria are burdened by high
mortality and represent an urgent threat to address. Clinicians are currently at a dawn of a …
mortality and represent an urgent threat to address. Clinicians are currently at a dawn of a …
The antibiotic pipeline for multi-drug resistant gram negative bacteria: what can we expect?
ME Falagas, AD Mavroudis… - Expert review of anti …, 2016 - Taylor & Francis
Introduction: A real concern in the medical community is the increasing resistance of
bacteria, especially that of Gram-negative types. New antibiotics are currently under clinical …
bacteria, especially that of Gram-negative types. New antibiotics are currently under clinical …